2022年坦桑尼亚蒿甲醚-苯芴醇治疗无并发症恶性疟感染的疗效与安全性:单臂临床试验
该单臂临床试验在坦桑尼亚4个哨点招募6月龄至10岁无并发症恶性疟患儿,采用蒿甲醚-苯芴醇标准6剂3天方案治疗并随访28天。352例入组者中55例出现寄生虫复发,PCR校正的Kaplan-Meier有效率在Pwani为89.9%、Kigoma为95.0%、Tanga为94.4%、Morogoro为98.9%,未发现K13突变。作者认为该药在3个地区仍高效,但Pwani有效率低于WHO推荐的90%政策变更阈值。
要点
- 352例患儿中55例寄生虫复发,4例退出。
- PCR校正有效率:Pwani 89.9%、Kigoma 95.0%、Tanga 94.4%、Morogoro 98.9%。
- 未检测到K13突变;Pwani有效率低于WHO 90%阈值。
核心结论
- 蒿甲醚-苯芴醇在坦桑尼亚3个地区仍高度有效,但Pwani的PCR校正有效率低于WHO推荐的90%政策变更阈值。
- 作者认为实施青蒿素联合疗法多样化策略以确保坦桑尼亚有效病例管理至关重要。
研究设计与样本
- 单臂临床试验,从4个哨点招募6月龄至10岁无并发症恶性疟患儿,每站点88例,共352例。
- 采用蒿甲醚-苯芴醇标准6剂3天方案治疗,按WHO标准方案随访28天临床和寄生虫学应答。
- 采用基于msp1、msp2和glurp的基因分型区分再燃与再感染,采用Sanger测序检测K13突变。
主要发现
- 352例入组者中4例退出,55例出现寄生虫复发。
- PCR校正的Kaplan-Meier有效率:Pwani 89.9%、Kigoma 95.0%、Tanga 94.4%、Morogoro 98.9%。
- 未发现K13突变。
关键数值与推荐
- WHO推荐的90%阈值:Pwani的PCR校正有效率89.9%低于该阈值,建议政策变更。
- 其他3个地区PCR校正有效率分别为Kigoma 95.0%、Tanga 94.4%、Morogoro 98.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemether-lumefantrine (AL) is the first-line antimalarial drug for the treatment of uncomplicated malaria in Tanzania. The World Health Organization (WHO) recommends regular efficacy monitoring of antimalarial drugs to inform case management policy decisions. This study assessed the safety and efficacy of AL for treating uncomplicated Plasmodium falciparum malaria in Tanzania in 2022. METHODS: Children aged 6 months to 10 years with uncomplicated P falciparum malaria were recruited from 4 sentinel sites and treated with the standard 6-dose, 3-day regimen for AL. Clinical and parasitological responses were monitored for 28 days using the WHO standard protocol. Genotyping based on msp1, msp2, and glurp was used to distinguish recrudescence from reinfection. Sanger sequencing was used to detect K13 mutations. RESULTS: Three hundred fifty-two participants, 88 per site, were enrolled. Four withdrew and 55 experienced parasite recurrence. The polymerase chain reaction (PCR)-corrected Kaplan-Meier efficacies were 89.9% in Pwani, 95.0% in Kigoma, 94.4% in Tanga, and 98.9% in Morogoro. No K13 mutations were found. CONCLUSIONS: Artemether-lumefantrine remains highly efficacious in 3 regions of Tanzania, but the PCR-corrected efficacy in Pwani fell below the WHO-defined 90% threshold at which policy change is recommended. Implementing strategies to diversify artemisinin-based combination therapies to ensure effective case management in Tanzania is critical.
引用
- Laury JE, Mugittu K, Kajeguka DC, et al. Efficacy and Safety of Artemether-Lumefantrine Against Uncomplicated Falciparum Malaria Infection in Tanzania, 2022: A Single-Arm Clinical Trial. J Infect Dis. 2025. PMID: 39186698. doi:10.1093/infdis/jiae425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。